唑来膦酸针与伊班膦酸钠针治疗骨肿瘤的临床效果分析  

Clinical Observation of Zoledronic Acid and Ibandronate in Treatment of Bone Neoplasms

作　　者：王健[1] 黄芬[2] 刘波[3] 周天宝[3] 李铁军[3] 周国强[4] 

机构地区：[1]湖南商学院综合门诊部,湖南长沙410205 [2]海南医学院肿瘤内科,海南海口570102 [3]中南大学湘雅三医院骨科,湖南长沙410013 [4]湖南师范大学医院,湖南长沙410013

出　　处：《肿瘤药学》2015年第6期454-457,共4页Anti-Tumor Pharmacy

基　　金：国家自然科学基金资助项目(81202730)

摘　　要：目的 比较唑来膦酸针与伊班膦酸钠针治疗骨肿瘤患者的临床效果和医疗费用。方法 选取2011年9月~2014年9月间收治入院的35例骨肿瘤患者为研究对象,随机分为A组（18例）和B组（17例）,A组患者采用唑来膦酸针治疗,B组患者采用伊班膦酸钠针治疗,比较两组患者的临床疗效、不良反应和医疗费用。结果 B组的疼痛缓解率及生活质量改善率显著优于A组（P〈0.05）,不良反应发生率显著低于A组（P〈0.05）,且B组患者产生的总医疗费用低于A组（P〈0.05）。结论 与唑来膦酸针比较,伊班膦酸钠针治疗骨肿瘤的临床疗效更显著,不良反应更少且产生的医疗费用较低,值得临床推广应用。Objective To evaluate the efficacy of zoledronic acid and ibandronate for bone neoplasms. Methods We selected 35 cases of patients with bone neoplasms from our hospital as the study objects. They were randomly divided into two groups： group A （18 eases） and group B （17 eases）. Patients in group A were treated with zoledronic acid, while patients in group B were treated with ibandronate sodium. The improvement of pain and the incidence of adverse reactions in the two groups were compared and analyzed. Results The rates of pain relief and improvement of quality of life in group B was significantly higher than in group A （P〈0.05）. The incidence of adverse reactions in group B was significantly lower than in group A （P〈0.05）. And the total medical cost of patients in group B was less than that in group A （P〈0.05）. Conclusion Compared with zoledronic acid, ibandronate had better clinical curative effect in treatment of bone tumors. It also had less adverse reaction and less medical expenses, so it is worthy of cfinieal application.

关 键 词：伊班膦酸 唑来膦酸 骨肿瘤 疗效分析 

分 类 号：R738.1[医药卫生—肿瘤]